STOCK TITAN
  1. Home
  2. Sec-filings
  3. EVGN
  4. [EFFECT] Evogene Ltd. SEC Filing

[EFFECT] Evogene Ltd. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: November 19, 2025
Accession Number: 0001178913-25-003429
Submission Type: POS AM
CIK: 0001574565
Company Name: Evogene Ltd.
File Number: 333-282218

Source: View Original Filing on SEC EDGAR

Stock EVGN logo
Evogene

NASDAQ:EVGN

EVGN Rankings

#6324 Ranked by Market Cap
N/A Ranked by Dividends

EVGN Latest News

Jan 7, 2026
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
Dec 30, 2025
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
Nov 11, 2025
Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming
Nov 6, 2025
Evogene Schedules Third Quarter 2025 Financial Results Release
Aug 28, 2025
Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

EVGN Latest SEC Filings

Nov 20, 2025
[6-K] Evogene Ltd. Current Report (Foreign Issuer)
Sep 30, 2025
[6-K] Evogene Ltd. Current Report (Foreign Issuer)
Sep 10, 2025
[6-K] EVOGENE LTD. Current Report (Foreign Issuer)
Aug 19, 2025
[6-K] EVOGENE LTD. Current Report (Foreign Issuer)
Aug 18, 2025
[6-K] EVOGENE LTD. Current Report (Foreign Issuer)

EVGN Stock Data

10.02M
8.63M
0.96%
1.61%
1.23%
Biotechnology
Healthcare
Link
Israel
Rehovot